Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis

医学 经皮冠状动脉介入治疗 心肌梗塞 旁路移植 内科学 心脏病学 动脉 冠状动脉疾病 左主干冠状动脉疾病 经皮 药物洗脱支架
作者
Marc S. Sabatine,Brian A. Bergmark,Sabina A. Murphy,Patrick T. O’Gara,Peter K. Smith,Patrick W. Serruys,A. Pieter Kappetein,Seung–Jung Park,Duk‐Woo Park,Evald Høj Christiansen,Niels Ramsing Holm,Per Hostrup Nielsen,Gregg W. Stone,Joseph F. Sabik,Eugene Braunwald
出处
期刊:The Lancet [Elsevier BV]
卷期号:398 (10318): 2247-2257 被引量:218
标识
DOI:10.1016/s0140-6736(21)02334-5
摘要

Background The optimal revascularisation strategy for patients with left main coronary artery disease is uncertain. We therefore aimed to evaluate long-term outcomes for patients treated with percutaneous coronary intervention (PCI) with drug-eluting stents versus coronary artery bypass grafting (CABG). Methods In this individual patient data meta-analysis, we searched MEDLINE, Embase, and the Cochrane database using the search terms “left main”, “percutaneous coronary intervention” or “stent”, and “coronary artery bypass graft*” to identify randomised controlled trials (RCTs) published in English between database inception and Aug 31, 2021, comparing PCI with drug-eluting stents with CABG in patients with left main coronary artery disease that had at least 5 years of patient follow-up for all-cause mortality. Two authors (MSS and BAB) identified studies meeting the criteria. The primary endpoint was 5-year all-cause mortality. Secondary endpoints were cardiovascular death, spontaneous myocardial infarction, procedural myocardial infarction, stroke, and repeat revascularisation. We used a one-stage approach; event rates were calculated by use of the Kaplan-Meier method and treatment group comparisons were made by use of a Cox frailty model, with trial as a random effect. In Bayesian analyses, the probabilities of absolute risk differences in the primary endpoint between PCI and CABG being more than 0·0%, and at least 1·0%, 2·5%, or 5·0%, were calculated. Findings Our literature search yielded 1599 results, of which four RCTs—SYNTAX, PRECOMBAT, NOBLE, and EXCEL—meeting our inclusion criteria were included in our meta-analysis. 4394 patients, with a median SYNTAX score of 25·0 (IQR 18·0–31·0), were randomly assigned to PCI (n=2197) or CABG (n=2197). The Kaplan-Meier estimate of 5-year all-cause death was 11·2% (95% CI 9·9–12·6) with PCI and 10·2% (9·0–11·6) with CABG (hazard ratio 1·10, 95% CI 0·91–1·32; p=0·33), resulting in a non-statistically significant absolute risk difference of 0·9% (95% CI −0·9 to 2·8). In Bayesian analyses, there was an 85·7% probability that death at 5 years was greater with PCI than with CABG; this difference was more likely than not less than 1·0% (<0·2% per year). The numerical difference in mortality was comprised more of non-cardiovascular than cardiovascular death. Spontaneous myocardial infarction (6·2%, 95% CI 5·2–7·3 vs 2·6%, 2·0–3·4; hazard ratio [HR] 2·35, 95% CI 1·71–3·23; p<0·0001) and repeat revascularisation (18·3%, 16·7–20·0 vs 10·7%, 9·4–12·1; HR 1·78, 1·51–2·10; p<0·0001) were more common with PCI than with CABG. Differences in procedural myocardial infarction between strategies depended on the definition used. Overall, there was no difference in the risk of stroke between PCI (2·7%, 2·0–3·5) and CABG (3·1%, 2·4–3·9; HR 0·84, 0·59–1·21; p=0·36), but the risk was lower with PCI in the first year after randomisation (HR 0·37, 0·19–0·69). Interpretation Among patients with left main coronary artery disease and, largely, low or intermediate coronary anatomical complexity, there was no statistically significant difference in 5-year all-cause death between PCI and CABG, although a Bayesian approach suggested a difference probably exists (more likely than not <0·2% per year) favouring CABG. There were trade-offs in terms of the risk of myocardial infarction, stroke, and revascularisation. A heart team approach to communicate expected outcome differences might be useful to assist patients in reaching a treatment decision. Funding No external funding.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI6.2的应助被action采纳,获得10
3秒前
ding的应助被小陈采纳,获得10
3秒前
执着的尔容完成签到,获得积分10
7秒前
研友_VZG7GZ的应助被863采纳,获得10
8秒前
Bright完成签到 ,获得积分10
9秒前
秋风的应助被DW采纳,获得10
11秒前
Pursue。完成签到,获得积分10
11秒前
13秒前
TPolymer完成签到,获得积分10
16秒前
脑洞疼的应助被扶竹苏春采纳,获得10
17秒前
化学废材完成签到,获得积分10
18秒前
CodeCraft的应助被hyska采纳,获得10
19秒前
含蓄书桃发布了新的文献求助10
20秒前
20秒前
21秒前
22秒前
健康的魔镜完成签到 ,获得积分10
24秒前
华无剑的应助被DW采纳,获得10
24秒前
25秒前
小乐乐完成签到 ,获得积分10
25秒前
斯文败类的应助被淡淡青枫采纳,获得10
27秒前
28秒前
山海不远发布了新的文献求助10
29秒前
uniphoton完成签到,获得积分10
30秒前
fatal发布了新的文献求助10
32秒前
111发布了新的文献求助10
32秒前
粥粥粥完成签到 ,获得积分10
33秒前
ding的应助被木木采纳,获得10
34秒前
叶上初阳完成签到,获得积分0
34秒前
干咸鱼叔叔完成签到,获得积分10
35秒前
GoGoGo完成签到,获得积分10
36秒前
hitech的应助被fatal采纳,获得10
38秒前
科研通AI6.2的应助被山海不远采纳,获得30
39秒前
含蓄书桃完成签到 ,获得积分10
39秒前
spark发布了新的文献求助10
40秒前
Crazy鑫完成签到,获得积分10
42秒前
43秒前
44秒前
快乐鼠完成签到,获得积分10
46秒前
47秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188339
求助须知:如何正确求助?哪些是违规求助? 9576127
关于积分的说明 21845709
捐赠科研通 7786389
什么是DOI,文献DOI怎么找? 3435292
关于科研通互助平台的介绍 2559588
邀请新用户注册赠送积分活动 2482196